Why 340B Matters More Than Ever w/ Scott Seidelmann, CEO, NuvemRx

Send us Fan MailFederally Qualified Health Centers (FQHCs) care for more than 30 million Americans, yet many people have never heard of them or understand how they stay afloat. A major piece of their financial survival is the 340B drug pricing program, which has quietly become one of the most important funding mechanisms in the safety net and it is under growing pressure.Scott Seidelmann, CEO of Nuvem, joins CareTalk hosts David E. Williams and John Driscoll to discuss how FQHCs serve underserved communities, why 340B has become essential to their operations, and what policy changes could make or break their ability to deliver care.🎙️⚕️ABOUT SCOTT SEIDELMANNAs Chief Executive Officer, Scott is responsible for overseeing all facets of the organization. Scott has more than 25 years of experience in provider‑oriented healthcare and pharmacy technology and services and brings a wealth of knowledge and experience in the 340B industry, with an emphasis on client success and growth. Most recently, Scott was the EVP and Chief Commercial Officer at Omnicell, a publicly traded pharmacy technology and services company serving primarily health systems. 🎙️⚕️ABOUT CARETALKCareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (Chairman, UConn Health) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy. GET IN TOUCHFollow CareTalk on LinkedInBecome a CareTalk sponsorGuest appearance requestsVisit us on the webSubscribe to the CareTalk NewsletterSupport the show⚙️CareTalk:  Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing Consulting.